Global Bone Morphogenetic Protein Market -2024-2031

Global Bone Morphogenetic Protein Market -2024-2031

Global bone morphogenetic protein market reached US$ YY million in 2023 and is expected to reach US$ YY million by 2031, growing at a CAGR of YY% during the forecast period 2024-2031.

Bone morphogenetic proteins (BMPs), originally identified as osteoinductive components in extracts derived from bone, are now known to play important roles in a wide array of processes during the formation and maintenance of various organs including bone, cartilage, muscle, kidney and blood vessels. BMPs and the related “growth and differentiation factors” (GDFs) are members of the transforming growth factor β (TGF-β) family, and transduce their signals through type I and type II serine–threonine kinase receptors and their intracellular downstream effectors, including Smad proteins.

Furthermore, BMP signals are finely tuned by various agonists and antagonists. Because deregulation of the BMP activity at multiple steps in signal transduction is linked to a wide variety of human diseases, therapeutic use of activators and inhibitors of BMP signaling will provide potential avenues for the treatment of the human disorders that are caused by hypo- and hyperactivation of BMP signals, respectively.

Market Dynamics: Drivers

Rising adoption of BMPs for spinal fusion procedures

The rising adoption of BMPs for spinal fusion procedures is expected to drive the market over the forecast period. Spinal fusion is a surgical procedure performed to join two or more vertebrae permanently, aiming to reduce pain and restore stability in the spine. BMPs play a crucial role in this process by promoting bone growth and facilitating the fusion of vertebrae. BMPs have shown efficacy in stimulating bone formation, essential for successful spinal fusion. By enhancing bone growth and fusion rates, BMPs can improve patient outcomes and reduce the risk of complications associated with failed fusion.

For instance, on May 19, 2023, the US Food and Drug Administration (FDA) granted breakthrough device designation for Locate Bio’s bone graft technology for patients with degenerative disc disease (DDD). Nottingham is developing a bone graft that releases osteoinductive recombinant human bone morphogenetic protein 2 (rhBMP-2), a protein that drives cell differentiation and bone formation. The protein is released from a three-dimensional, resorbable tissue scaffold and provides extended release as the scaffold system degrades. The graft will be used for anterior lumbar interbody spinal fusion (ALIF) procedures for patients with DDD. There are an estimated 400 million people diagnosed globally with pathologic disc degeneration each year.

Advances in surgical techniques have led to the development of minimally invasive spinal fusion procedures. BMPs can be delivered locally at the surgical site, allowing for targeted bone regeneration without the need for extensive tissue dissection. This minimally invasive approach reduces surgical trauma, postoperative pain and recovery time, thus contributing to the rising adoption of BMPs in spinal fusion surgeries.

Further, the rising geriatric population, rising preference for minimally invasive surgeries and adoption of BMPs in various surgeries are the factors expected to drive the market over the forecast period.

Restraints

Factors such as the high cost of BMP products, availability of alternative bone graft materials, limited clinical evidence and regulatory challenges are the factors expected to hamper the bone morphogenetic protein market.

For more details on this report - Request for Sample

Segment Analysis

The global bone morphogenetic protein market is segmented based on type, application, end-user and region.

The rhBMP-2 segment accounted for approximately 45.3% of the bone morphogenetic protein market share

The rhBMP-2 segment is expected to hold the largest market share over the forecast period. Clinical studies have demonstrated the efficacy of rhBMP-2 in bone regeneration and facilitating spinal fusion. It has shown comparable or superior fusion rates when compared to traditional bone grafting materials in various spinal fusion procedures.

For instance, on February 21, 2022, Okayama University launched clinical trials of a jawbone regeneration therapy using human BMP-2 transgenic protein derived from Escherichia coli. Bone morphogenetic protein (BMP-2) -based bone regeneration therapy shows potential as being the most effective form of regenerative treatment. Human bones contain BMP-2, and importantly, when this protein is transplanted together with a carrier to other parts of the body that do not have bones, then bones can be ectopically formed.

rhBMP-2 reduces the need for autologous bone grafts, which are often harvested from the patient's own body, leading to additional surgical morbidity, prolonged operative time and increased costs. By eliminating or reducing reliance on autografts, rhBMP-2 simplifies the surgical procedure and reduces patient discomfort. rhBMP-2 promotes predictable bone formation at the fusion site, leading to consistent and reliable outcomes in spinal fusion procedures.

Geographical Analysis

North America accounted for approximately 42.5% of the market share

North America region is expected to hold the largest market share over the forecast period owing to the strong presence of major players and increasing research activities. North America especially the United States is very well-known for its strong presence of major players such as Stryker Corporation, Thermo Fisher Scientific Inc. and Merck KGaA among others. This presence of major players in the region has huge research evidence for their BMP products.

In addition, there is an increasing research activities for BMPs in the region, especially in the United States and Canada. Both the United States and Canada are major hubs for clinical trials and research in healthcare. Clinical studies evaluating the safety, efficacy and therapeutic potential of BMPs are conducted across various medical specialties, including orthopedics, neurosurgery, dentistry and maxillofacial surgery.

For instance, in September 2020, The peptide-enhanced bone graft, i-FACTOR+ Matrix, from Cerapedics, Inc. received approval from Health Canada. Canada is the first market to approve the launch of the new bone graft. OTW recently covered the progress of the new material, also referred to as P15-L in a U.S. investigational device exemption (IDE) study named ASPIRE. Clinical studies have shown superiority to autograft and equivalence to bone morphogenetic protein-based biologics, without the undesirable side-effects associated with them.

Competitive Landscape

The major global players in the bone morphogenetic protein market include Medtronic plc, Stryker Corporation, Thermo Fisher Scientific Inc., Merck KGaA, Bio-Techne, Proteintech Group, Inc., FUJIFILM Wako Pure Chemical Corporation, REPROCELL Inc., Biomol GmbH and Neuromics among others.

COVID-19 Impact Analysis

The COVID-19 pandemic significantly impacted the global bone morphogenetic protein market. According to the National Institute of Health, several lines of evidence indicate that agonists of the BMP signaling pathway may be useful for the treatment of SARS-COVID-19 pulmonary, cardiac, and kidney injuries. BMPs are phylogenetically conserved signaling molecules that belong to the TGF-β protein superfamily.

BMPs signal through serine and/or threonine kinase receptors, which are composed of type I and II subtypes that are required for signal transduction. Accordingly, harnessing the BMP pathway would appear to hold the potential for a treatment strategy for the multiorgan injuries prevalent in patients with COVID-19.

Market Segmentation

By Type
• rhBMP-2
• rhBMP-4
• rhBMP-6
• rhBMP-7
• Others

By Application
• Spinal Fusion
• Trauma
• Reconstructive Surgery
• Oral-Maxillofacial Surgery
• Others

By End-User
• Hospitals
• Specialty Clinics
• Ambulatory Surgical Centers
• Orthopedic Centers
• Others

By Region
• North America
U.S.
Canada
Mexico
• Europe
Germany
U.K.
France
Spain
Italy
Rest of Europe
• South America
Brazil
Argentina
Rest of South America
• Asia-Pacific
China
India
Japan
South Korea
Rest of Asia-Pacific
• Middle East and Africa

Why Purchase the Report?
• To visualize the global bone morphogenetic protein market segmentation based on type, application, end-user and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development
• Excel data sheet with numerous data points of bone morphogenetic protein market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global bone morphogenetic protein market report would provide approximately 61 tables, 63 figures and 184 Pages.

Target Audience 2024
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies